Sebastien Maloveste - NextCure Senior Development
| NXTC Stock | USD 0.79 0.02 2.60% |
Executive
Sebastien Maloveste is Senior Development of NextCure
| Phone | 240 399 4900 |
| Web | https://www.nextcure.com |
NextCure Management Efficiency
The company has return on total asset (ROA) of (0.3109) % which means that it has lost $0.3109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5475) %, meaning that it created substantial loss on money invested by shareholders. NextCure's management efficiency ratios could be used to measure how well NextCure manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Moses Makunje | Nuvation Bio | 45 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Anuj MD | Assembly Biosciences | 47 | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Amy CFA | Assembly Biosciences | N/A | |
| Colleen Sjogren | Nuvation Bio | 55 | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Philippe Sauvage | Nuvation Bio | 48 | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| YuWaye MD | CytomX Therapeutics | 57 | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Thomas Rollins | Assembly Biosciences | 69 | |
| Tamara LLM | Spero Therapeutics | 62 | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.31 |
NextCure Leadership Team
Elected by the shareholders, the NextCure's board of directors comprises two types of representatives: NextCure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NextCure. The board's role is to monitor NextCure's management team and ensure that shareholders' interests are well served. NextCure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NextCure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Steven CPA, Chief Officer | ||
| Sebastien Maloveste, Senior Development | ||
| Sourav Kundu, Senior Manufacturing | ||
| Kevin Shaw, General Counsel | ||
| Michael MSBA, CEO, CoFounder | ||
| Lieping MD, CoFounder Board | ||
| Timothy Mayer, Chief Officer | ||
| MD FACP, Chief Officer | ||
| Udayan MD, Senior Development | ||
| Solomon Langermann, Chief Officer | ||
| Stacy Rollinger, Vice Resources |
NextCure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NextCure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (47.82 M) | ||||
| Shares Outstanding | 28.01 M | ||||
| Shares Owned By Insiders | 8.85 % | ||||
| Shares Owned By Institutions | 57.50 % | ||||
| Number Of Shares Shorted | 94.89 K | ||||
| Price To Earning | (25.44) X | ||||
| Price To Book | 0.29 X | ||||
| Price To Sales | 9.52 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.